Pluri Completes First Phase of Resbiomed Program for Placenta-Derived Biomaterials.
ByAinvest
Thursday, Jan 22, 2026 8:33 am ET1min read
PLUR--
Pluri, Inc. has completed the first phase of its program with Resbiomed Technologies OOD to develop extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program aims to enhance, standardize, and enable scalable production of placenta-derived biomaterials containing naturally occurring human collagen. PluriCDMO, the company's contract development and manufacturing division, is applying its proprietary placenta-derived processing and bioprocessing capabilities to support Resbiomed. The collaboration aims to expand access to regenerative medicine, advanced wound care, medical devices, and other applications.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet